{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:57:47Z","timestamp":1772146667941,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10497-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:40:58Z","timestamp":1744360858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors"],"prefix":"10.1007","volume":"52","author":[{"given":"Leonidas","family":"Benetatos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Hatzimichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Kapsali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"10497_CR1","doi-asserted-by":"crossref","first-page":"a014191","DOI":"10.1101\/cshperspect.a014191","volume":"4","author":"A Sabo","year":"2014","unstructured":"Sabo A, Amati B (2014) Genome recognition by MYC. Cold Spring Harb Perspect Med 4:a014191","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10497_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00109-020-01891-1","volume":"98","author":"L Benetatos","year":"2020","unstructured":"Benetatos L, Benetatou A, Vartholomatos G (2020) Enhancers and MYC interplay in hematopoiesis. J Mol Med (Berl) 98:471\u2013481","journal-title":"J Mol Med (Berl)"},{"key":"10497_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00018-013-1426-x","volume":"71","author":"B Benetatos","year":"2014","unstructured":"Benetatos B, Vartholomatos G, Hatzimichael E (2014) Polycomb group proteins and MYC: the cancer connection. Cell Mol Life Sci 71:257\u2013269","journal-title":"Cell Mol Life Sci"},{"key":"10497_CR4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccell.2018.09.001","volume":"34","author":"WB Tu","year":"2018","unstructured":"Tu WB, Shiah YJ, Lourenco C et al (2018) MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell 34:579\u2013595e8","journal-title":"Cancer Cell"},{"issue":"7510","key":"10497_CR5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature13473","volume":"511","author":"S Walz","year":"2014","unstructured":"Walz S, Lorenzin F, Morton J et al (2014) Activation and repression by oncogenic MYC shape tumor-specific gene expression profiles. Nature 511(7510):483\u2013487","journal-title":"Nature"},{"key":"10497_CR6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","volume":"151","author":"Z Nie","year":"2012","unstructured":"Nie Z, Hu G, Wei G et al (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151:68\u201379","journal-title":"Cell"},{"key":"10497_CR7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nature13537","volume":"511","author":"A Sab\u00f2","year":"2014","unstructured":"Sab\u00f2 A, Kress TR, Pelizzola M et al (2014) Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511:488\u2013492","journal-title":"Nature"},{"key":"10497_CR8","doi-asserted-by":"crossref","first-page":"110292","DOI":"10.1016\/j.celrep.2021.110292","volume":"38","author":"S Patange","year":"2022","unstructured":"Patange S, Ball DA, Yihan Wan Y et al (2022) MYC amplifies gene expression through global changes in transcription factor dynamics. Cell Rep 38:110292","journal-title":"Cell Rep"},{"key":"10497_CR9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang J, Yin J et al (2021) Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther 6:117","journal-title":"Signal Transduct Target Ther"},{"key":"10497_CR10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","volume":"21","author":"C Lourenco","year":"2021","unstructured":"Lourenco C, Resetca D, Redel C et al (2021) MYC protein interactors in gene transcription and cancer. Nat Rev Cancer 21:579\u2013591","journal-title":"Nat Rev Cancer"},{"key":"10497_CR11","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00277-020-04166-4","volume":"99","author":"L Benetatos","year":"2020","unstructured":"Benetatos L, Benetatou A, Vartholomatos G (2020) Long non-coding RNAs and MYC association in hematological malignancies. Ann Hematol 99:2231\u20132242","journal-title":"Ann Hematol"},{"key":"10497_CR12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD et al (2022) The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol 19:23\u201336","journal-title":"Nat Rev Clin Oncol"},{"key":"10497_CR13","doi-asserted-by":"crossref","first-page":"112401","DOI":"10.1016\/j.celrep.2023.112401","volume":"42","author":"C Liu","year":"2023","unstructured":"Liu C, Kudo T, Ye X, Gascoigne K (2023) Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. Cell Rep 42:112401","journal-title":"Cell Rep"},{"key":"10497_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.33197","volume":"148","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ (2021) CrownJ. Drugging undruggable genes for cancer treatment: are we making progress? Int J Cancer 148:8\u201317","journal-title":"Int J Cancer"},{"key":"10497_CR15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tips.2024.04.008","volume":"45","author":"PE Thompson","year":"2024","unstructured":"Thompson PE, Shortt J (2024) Defeating MYC with drug combinations or dual-targeting drugs. Trends Pharmacol Sci 45:490\u2013502","journal-title":"Trends Pharmacol Sci"},{"key":"10497_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/iub.2773","volume":"76","author":"S Newell","year":"2024","unstructured":"Newell S, van der Watt PJ, Leaner VD (2024) Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy. IUBMB Life 76:4\u201325","journal-title":"IUBMB Life"},{"key":"10497_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q (2023) Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther 8:425","journal-title":"Signal Transduct Target Ther"},{"key":"10497_CR18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM (2021) The nuclear export protein XPO1 - from biology to targeted therapy. Nat Rev Clin Oncol 18:152\u2013169","journal-title":"Nat Rev Clin Oncol"},{"key":"10497_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, Sola B, Jardin F (2017) XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol 10:47","journal-title":"J Hematol Oncol"},{"key":"10497_CR20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","volume":"9","author":"J Taylor","year":"2019","unstructured":"Taylor J, Sendino M, Gorelick AN et al (2019) Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov 9:1452\u20131467","journal-title":"Cancer Discov"},{"key":"10497_CR21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund K, Bruinink DHO, Coward E et al (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia 36:1887\u20131897","journal-title":"Leukemia"},{"key":"10497_CR22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551\u2013568e14","journal-title":"Cancer Cell"},{"key":"10497_CR23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bjh.19052","volume":"203","author":"R Moia","year":"2023","unstructured":"Moia R, Terzi di Bergamo L, Talotta D et al (2023) XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. Br J Haematol 203:416\u2013425","journal-title":"Br J Haematol"},{"key":"10497_CR24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","volume":"36","author":"SK Balasubramanian","year":"2022","unstructured":"Balasubramanian SK, Azmi AS, Maciejewski J (2022) Selective Inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia 36:601\u2013612","journal-title":"Leukemia"},{"key":"10497_CR25","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","volume":"34","author":"B Nachmias","year":"2020","unstructured":"Nachmias B, Schimmer AD (2020) Targeting nuclear import and export in hematological malignancies. Leukemia 34:2875\u20132886","journal-title":"Leukemia"},{"key":"10497_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-23-1992","volume":"84","author":"R Marullo","year":"2024","unstructured":"Marullo R, Rutherford SC, Revuelta MV et al (2024) XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells. Cancer Res 84:101\u2013117","journal-title":"Cancer Res"},{"key":"10497_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","volume":"45","author":"L Golomb","year":"2012","unstructured":"Golomb L, Bublik DR, Sylvia Wilder S et al (2012) Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 45:222\u2013232","journal-title":"Mol Cell"},{"key":"10497_CR28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41419-024-06965-3","volume":"15","author":"M Grze\u015b","year":"2024","unstructured":"Grze\u015b M, Jaiswar A, Grochowski M et al (2024) A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. Cell Death Dis 15:638","journal-title":"Cell Death Dis"},{"key":"10497_CR29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2767-9764.CRC-21-0176","volume":"2","author":"H Yar Kahn","year":"2022","unstructured":"Yar Kahn H, Nagasaka M, Li Y et al (2022) Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C-Mutant cancers. Cancer Res Commun 2:342\u2013352","journal-title":"Cancer Res Commun"},{"key":"10497_CR30","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-19-0273","volume":"25","author":"F Lucas","year":"2019","unstructured":"Lucas F, Rogers KA, Harrington BK et al (2019) E\u00b5-TCL1xMyc: A novel mouse model for concurrent CLL and B-Cell lymphoma. Clin Cancer Res 25:6260\u20136273","journal-title":"Clin Cancer Res"},{"key":"10497_CR31","doi-asserted-by":"crossref","first-page":"eadh1436","DOI":"10.1126\/sciadv.adh1436","volume":"9","author":"Y Nishida","year":"2023","unstructured":"Nishida Y, Ishizawa J, Ayoub E et al (2023) Enhanced P53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9:eadh1436","journal-title":"Sci Adv"},{"key":"10497_CR32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","volume":"11","author":"P Lu","year":"2021","unstructured":"Lu P, Wang S, Franzen CA et al (2021) Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J 11:39","journal-title":"Blood Cancer J"},{"key":"10497_CR33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2014.260","volume":"111","author":"H Sun","year":"2014","unstructured":"Sun H, Hattori N, Chien W et al (2014) KPT-330 has antitumor activity against non-small cell lung cancer. Br J Cancer 111:281\u2013291","journal-title":"Br J Cancer"},{"key":"10497_CR34","doi-asserted-by":"crossref","first-page":"e0137210","DOI":"10.1371\/journal.pone.0137210","volume":"10","author":"Y Tabe","year":"2015","unstructured":"Tabe Y, Kojima K, Yamamoto S et al (2015) Ribosomal biogenesis and translational flux Inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS ONE 10:e0137210","journal-title":"PLoS ONE"},{"key":"10497_CR35","doi-asserted-by":"crossref","first-page":"18554","DOI":"10.1038\/s41598-023-45721-z","volume":"13","author":"M Deng","year":"2023","unstructured":"Deng M, Tan J, Fan Z et al (2023) The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep 13:18554","journal-title":"Sci Rep"},{"key":"10497_CR36","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Braggio E, Kortuem KM et al (2013) XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 27:2357\u20132365","journal-title":"Leukemia"},{"issue":"1","key":"10497_CR37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Azizian NG, Dou Y, Pham LV, Li Y (2019) Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol 12(1):119","journal-title":"J Hematol Oncol"},{"key":"10497_CR38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jha2.709","volume":"4","author":"CC Mo","year":"2023","unstructured":"Mo CC, Yee AJ, Midha S et al (2023) Selinexor: targeting a novel pathway in multiple myeloma. EJHaem 4:792\u2013810","journal-title":"EJHaem"},{"key":"10497_CR39","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/cancers12061532","volume":"12","author":"M Grzes","year":"2020","unstructured":"Grzes M, Oron M, Staszczak Z et al (2020) A driver never works Alone-Interplay networks of mutant p53, MYC, RAS, and other universal oncogenic drivers in human cancer. Cancers (Basel) 12:1532","journal-title":"Cancers (Basel)"},{"key":"10497_CR40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","volume":"15","author":"S Li","year":"2016","unstructured":"Li S, Fu J, Lu C et al (2016) Elevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myeloma. Mol Cancer Ther 15:711\u2013719","journal-title":"Mol Cancer Ther"},{"key":"10497_CR41","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/bloodadvances.2021006638","volume":"7","author":"S Li","year":"2023","unstructured":"Li S, Fu J, Walker CJ et al (2023) Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Adv 7:2926\u20132937","journal-title":"Blood Adv"},{"key":"10497_CR42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","volume":"2","author":"B Culjkovic-Kraljacic","year":"2012","unstructured":"Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KLB (2012) The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep 2:207\u2013215","journal-title":"Cell Rep"},{"key":"10497_CR43","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.3390\/ijms24076816","volume":"24","author":"H Long","year":"2023","unstructured":"Long H, Hou Y, Li J, Song C, Ge Z (2023) Azacitidine is synergistically lethal with XPO1 inhibitor Selinexor in acute myeloid leukemia by targeting XPO1\/eIF4E\/c-MYC signaling. Int J Mol Sci 24:6816","journal-title":"Int J Mol Sci"},{"key":"10497_CR44","doi-asserted-by":"crossref","first-page":"217080","DOI":"10.1016\/j.canlet.2024.217080","volume":"597","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen J, Gao Y et al (2024) CDK4\/6 Inhibition augments anti-tumor efficacy of XPO1 inhibitor Selinexor in natural killer\/T-cell lymphoma. Cancer Lett 597:217080","journal-title":"Cancer Lett"},{"key":"10497_CR45","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.0606108103","volume":"103","author":"T Palomero","year":"2006","unstructured":"Palomero T, Lim WK, Odom DT et al (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103:18261\u201318266","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10497_CR46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, Micinski AM, Kastner DW et al (2020) MYC drives Temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38:60\u201378e12","journal-title":"Cancer Cell"},{"key":"10497_CR47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y et al (2024) Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther 9:128","journal-title":"Signal Transduct Target Ther"},{"key":"10497_CR48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101\u2013105","journal-title":"Nature"},{"key":"10497_CR49","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.18632\/oncotarget.1813","volume":"5","author":"J Gao","year":"2014","unstructured":"Gao J, Azmi AS, Aboukameel A et al (2014) Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget 5:3444\u20133454","journal-title":"Oncotarget"},{"key":"10497_CR50","doi-asserted-by":"crossref","first-page":"a014209","DOI":"10.1101\/cshperspect.a014209","volume":"4","author":"S Cermelli","year":"2014","unstructured":"Cermelli S, Jang IS, Bernard B, Grandori C (2014) Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4:a014209","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10497_CR51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tips.2020.11.014","volume":"42","author":"DKH Thng","year":"2021","unstructured":"Thng DKH, Toh TB, Chow EKHC (2021) Capitalizing on synthetic lethality of MYC to treat cancer in the digital age. Trends Pharmacol Sci 42:166\u2013182","journal-title":"Trends Pharmacol Sci"},{"key":"10497_CR52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41467-024-45128-y","volume":"15","author":"A Deutzmann","year":"2024","unstructured":"Deutzmann A, Sullivan DK, Dhanasekaran R et al (2024) Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. Nat Commun 15:963","journal-title":"Nat Commun"},{"key":"10497_CR53","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X et al (2016) XPO1 Inhibition using Selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus. Clin Cancer Res 22:6142\u20136152","journal-title":"Clin Cancer Res"},{"key":"10497_CR54","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jcmm.17274","volume":"26","author":"H Yu","year":"2022","unstructured":"Yu H, Wu S, Shuang Liu S et al (2022) Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. J Cell Mol Med 26:2646\u20132657","journal-title":"J Cell Mol Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10497-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:24:44Z","timestamp":1766852684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10497-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10497"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10497-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"386"}}